Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management
will participate in the following upcoming investor conferences. The
presentations will be webcast live and available for replay from Seattle
Genetics’ website, www.seattlegenetics.com,
under the “News and Investor Information” section.
Bank of America and Merrill Lynch 2009 Health Care Conference
Clay B. Siegall, Ph.D., President and Chief Executive Officer, will
speak on Wednesday, May 13, 2009, at 1:20 p.m. Eastern Time. The
conference is being held at The Palace Hotel in New York, NY.
Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer, will present on
Wednesday, May 20, 2009, at 3:15 p.m. Eastern Time. The conference is
being held at The Roosevelt Hotel in New York, NY.
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on
the development and commercialization of monoclonal antibody-based
therapies for the treatment of cancer and autoimmune disease. The
company’s lead product candidate, SGN-35, is in a pivotal trial under a
special protocol assessment with the FDA. SGN-35 is empowered by Seattle
Genetics’ proprietary ADC technology comprising highly potent synthetic
drugs and stable linkers for attaching the drugs to monoclonal
antibodies. In addition, Seattle Genetics has three other product
candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab
(SGN-33) and SGN-70. Dacetuzumab is being developed under a worldwide
collaboration with Genentech (a wholly owned member of the Roche Group).
Seattle Genetics has collaborations for its ADC technology with a number
of leading biotechnology and pharmaceutical companies, including
Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo, MedImmune, a
subsidiary of AstraZeneca, and Millennium: The Takeda Oncology Company,
as well as an ADC co-development agreement with Agensys, a subsidiary of
Astellas Pharma. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
